DOSING AND ADMINISTRATION

 -

MENVEO is approved in two presentations1

  • 1-vial presentation for use in individuals 10 through 55 years of age
  • 2-vial presentation for use in individuals 2 months through 55 years of age

Please see the Dear Healthcare Provider Letter for a summary of the differences between the MENVEO 1-vial and 2-vial presentations.

FDA-approved MENVEO dosing for adolescents and adults

FDA-approved MENVEO dosing for adolescents and adults

PRIMARY
VACCINATION

SINGLE DOSE (0.5 mL) in adolescents and adults aged 10 through 55 years1

SINGLE DOSE (0.5 mL) in adolescents and adults aged 10 through 55 years1

BOOSTER
VACCINATION

SINGLE BOOSTER dose (0.5 mL) in individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose (0.5 mL) of a meningitis ACWY (MenACWY) vaccine1

SINGLE BOOSTER dose (0.5 mL) in individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose (0.5 mL) of a meningitis ACWY (MenACWY) vaccine1

Administering MENVEO 1-vial presentation

Administering MENVEO 1-vial presentation

MENVEO 1-vial presentation is a solution for intramuscular injection supplied in a single vial with a pink cap and does NOT require reconstitution. Withdraw 0.5 mL from the vial and administer intramuscularly.1

FDA-approved MENVEO dosing for infants, adolescents, and adults

FDA-approved MENVEO dosing for infants, adolescents, and adults

PRIMARY
VACCINATION

SINGLE DOSE (0.5 mL) in adolescents and adults aged 10 through 55 years1

SINGLE DOSE (0.5 mL) in adolescents and adults aged 10 through 55 years1

BOOSTER
VACCINATION

SINGLE BOOSTER dose (0.5 mL) in individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose (0.5 mL) of a meningitis ACWY (MenACWY) vaccine1

SINGLE BOOSTER dose (0.5 mL) in individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose (0.5 mL) of a meningitis ACWY (MenACWY) vaccine1

MENVEO 2-vial presentation dosing for infants and young children

MENVEO 2-vial presentation is the only MenACWY vaccine approved for use in the US for infants as young as 2 months of age.1-3

MENVEO 2-vial presentation dosing for infants and young children

MENVEO 2-vial presentation is the only MenACWY vaccine approved for use in the US for infants as young as 2 months of age.1-3

2 MONTHS
OF AGE

4-DOSE SERIES with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age1

4-DOSE SERIES with a single dose (0.5 mL) at 2, 4, 6, and 12 months of age1

7 THROUGH 23
MONTHS OF AGE

2-DOSE SERIES (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose1

2-DOSE SERIES (0.5 mL each) with the second dose administered in the second year of life, at least 3 months after the first dose1

2 THROUGH 10
YEARS OF AGE

A SINGLE DOSE (0.5 mL). For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose (0.5 mL) may be administered 2 months after the first dose1

A SINGLE DOSE (0.5 mL). For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose (0.5 mL) may be administered 2 months after the first dose1

11 THROUGH 55
YEARS OF AGE

A SINGLE DOSE (0.5 mL)1
A SINGLE BOOSTER DOSE (0.5 mL) may be administered to individuals who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a MenACWY vaccine

A SINGLE DOSE (0.5 mL)1
A SINGLE BOOSTER DOSE (0.5 mL) may be administered to individuals who are at continued risk for meningococcal disease if at least 4 years have elapsed since a prior dose of a MenACWY vaccine

Safety and effectiveness of MENVEO 1-vial presentation in children aged younger than 10 years have not been established1

 -

Reconstitution for MENVEO 2-vial presentation

MENVEO 2-vial presentation is a solution for intramuscular injection supplied in 2 vials, the contents of which must be combined prior to administration.1

  • MenCYW-135 liquid conjugate component (gray cap)
  • MenA lyophilized conjugate component (orange cap)

After reconstitution, a single dose of MENVEO is 0.5 mL.1 Please note that neither component should be given alone.

MENVEO 2-vial presentation can be reconstituted in 3 steps1: PULL, MIX, and SHAKE

Syringe pulling contents from tilted Vial 1

PULL the entire contents of
MenCYW-135 liquid conjugate (Vial 1)
from the vial while slightly tilting.1

Syringe putting contents into Vial 2

MIX the MenCYW-135 liquid with the
MenA lyophilized conjugate (Vial 2).1

Syringe inserted into Vial 2, both upside-down

INVERT the vial and SHAKE well until the
lyophilized conjugate component is
completely dissolved.1

Invert the vial and SHAKE well until the lyophilized conjugate component is completely dissolved.1

After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly.1

 -

SEE THE DATA

Vaccination may not protect all recipients.